Business Description
4d pharma PLC
Share Class Description:
LBPWQ: Warrants (22/02/2025)Compare
Compare
Traded in other countries / regions
4DY.GermanyDDDD.UK IPO Date
2021-03-23Description
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.56 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -8.3 | |||||
| Beneish M-Score | -5.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4 | |||||
| 3-Year EPS without NRI Growth Rate | 6.9 | |||||
| 3-Year FCF Growth Rate | 26.3 | |||||
| 3-Year Book Growth Rate | -43.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.21 | |||||
| Quick Ratio | 5.16 | |||||
| Cash Ratio | 3.17 | |||||
| Days Sales Outstanding | 1799.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -40.2 | |||||
| Shareholder Yield % | -25.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -5082.18 | |||||
| Net Margin % | -10337.16 | |||||
| ROE % | -204.06 | |||||
| ROA % | -128.47 | |||||
| ROIC % | -108.4 | |||||
| ROC (Joel Greenblatt) % | -820.34 | |||||
| ROCE % | -158.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | N/A |
N/A
|
N/A
| |||
| PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
| PS Ratio | 0.06 | |||||
| EV-to-FCF | -0.97 | |||||
| FCF Yield % | -30.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LBPWQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4d pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 0.0001 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.0001 - 0.0001 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4d pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4d pharma PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
4d pharma PLC Frequently Asked Questions
What is 4d pharma PLC(LBPWQ)'s stock price today?
The current price of LBPWQ is $0.00. The 52 week high of LBPWQ is $0.00 and 52 week low is $0.00.
When is next earnings date of 4d pharma PLC(LBPWQ)?
The next earnings date of 4d pharma PLC(LBPWQ) is 2025-02-28 Est..
Does 4d pharma PLC(LBPWQ) pay dividends? If so, how much?
4d pharma PLC(LBPWQ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers